The use of dendritic cells for peptide-based vaccination in cancer immunotherapy

Methods in Molecular Biology

Volumn 1139, Issue , 2014, Pages 479-503

  Salem, Mohamed L ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Cancer; Dendritic cells; Immunotherapy; Peptide; T cells; Tumor; Vaccination

Indexed keywords

DENDRITIC CELL VACCINE; PEPTIDE VACCINE; TUMOR ANTIGEN; PEPTIDE;

ANTIGEN PRESENTING CELL; ARTICLE; BONE MARROW; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; DENDRITIC CELL; HUMAN; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINATION; ANIMAL; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM; REVIEW; TRANSPLANTATION;

ANIMALS; ANTIGENS, NEOPLASM; DENDRITIC CELLS; HUMANS; NEOPLASMS; PEPTIDES; VACCINATION;

EID: 84909587118     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-0345-0_37     Document Type: Article

References (157)

1. Matzinger P (2002) The danger model: a renewed sense of self. Science 296(5566): 301-305.
2. Finn OJ (2008) Cancer immunology. N Engl J Med 358(25): 2704-2715.
3. McCarthy EF (2006) The toxins of William B. Coley and the treatment of bone and softtissue sarcomas. Iowa Orthop J 26: 154-158.
4. Finn OJ (2008) Immunological weapons acquired early in life win battles with cancer late in life. J Immunol 181(3): 1589-1592.
5. Pejawar-Gaddy S, Finn OJ (2008) Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 67(2): 93-102.
6. Salem ML et al (2007) Tumours: immunotherapy. Encyclopedia of life sciences, 2007, John Wiley & Sons, Ltd. www. els. net.
7. Yannelli JR, Wroblewski JM (2004) On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine 23(1): 97-113.
8. Vermorken JB et al (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 353(9150): 345-350.
9. Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3): 372-383.
10. Banchereau J et al (2003) Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found Symp 252: 226-235, discussion 235-228, 257-267.
11. Stift A et al (2003) Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21(1): 135-142.
12. Brossart P (2002) Dendritic cells in vaccination therapies of malignant diseases. Transfus Apher Sci 27(2): 183-186.
13. Nagorsen D, Thiel E (2006) Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12(10): 3064-3069.
14. Steinman RM, Cohn ZA (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 137(5): 1142-1162.
15. Rosenzwajg M et al (1996) Human dendritic cell differentiation pathway from CD34 + hematopoietic precursor cells. Blood 87(2): 535-544.
16. Strobl H et al (1996) TGF-beta 1 promotes in vitro development of dendritic cells from CD34 + hemopoietic progenitors. J Immunol 157(4): 1499-1507.
17. Yao V et al (2002) Dendritic cells. ANZ J Surg 72(7): 501-506.
18. Reid CD (1997) The dendritic cell lineage in haemopoiesis. Br J Haematol 96(2): 217-223.
19. Szabolcs P et al (1996) Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colonyforming unit intermediate. Blood 87(11): 4520-4530.
20. Rossi G et al (1992) Development of a Langerhans cell phenotype from peripheral blood monocytes. Immunol Lett 31(2): 189-197.
21. Kasinrerk W et al (1993) CD1 molecule expression on human monocytes induced by granulocyte-macrophage colony-stimulating factor. J Immunol 150(2): 579-584.
22. Zhou LJ, Tedder TF (1996) CD14 + blood monocytes can differentiate into functionally mature CD83 + dendritic cells. Proc Natl Acad Sci USA 93(6): 2588-2592.
23. den Brok MH et al (2005) Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 4(5): 699-710.
24. Morisaki T et al (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16(4): 175-182.
25. Tacken PJ et al (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7(10): 790-802.
26. Caux C et al (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360(6401): 258-261.
27. Cella M et al (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184(2): 747-752.
28. Whiteside TL, Odoux C (2004) Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 53(3): 240-248.
29. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673): 245-252.
30. Aarntzen EH et al (2008) Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57(10): 1559-1568.
31. Nicola M et al (1999) The influence of interleukin (IL)-4 and IL-13 on human dendritic cell differentiation from CD34 + progenitor cells: the importance of the source of serum. Exp Hematol 27(2): 386-387.
32. Esche C et al (1999) The use of dendritic cells for cancer vaccination. Curr Opin Mol Ther 1(1): 72-81.
33. Zhang SN et al (2011) Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. [Research Support, Non-U. S. Gov't]. Mol Ther 19(8): 1558-1568.
34. Brinkman JA et al (2004) Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther 4(2): 181-198.
35. Kavanagh B et al (2007) Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 30(7): 762-772.
36. Harley CB et al (1990) Telomeres shorten during ageing of human fibroblasts. Nature 345(6274): 458-460.
37. Cong YS et al (2002) Human telomerase and its regulation. Microbiol Mol Biol Rev 66(3): 407-425.
38. Vonderheide RH (2008) Prospects and challenges of building a cancer vaccine targeting telomerase. Biochimie 90(1): 173-180.
39. Vonderheide RH et al (2004) Vaccination of cancer patients against telomerase induces functional antitumor CD8 + T lymphocytes. Clin Cancer Res 10(3): 828-839.
40. Su Z et al (2005) Telomerase mRNAtransfected dendritic cells stimulate antigenspecific CD8 + and CD4 + T cell responses in patients with metastatic prostate cancer. J Immunol 174(6): 3798-3807.
41. Kono K et al (2002) Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8(11): 3394-3400.
42. Aloysius M et al (2009) Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs. [Research Support, Non-U. S. Gov't]. J Transl Med 7: 18.
43. Suso EM et al (2011) hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 60(6): 809-818.
44. Terada T et al (1996) Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol 180(2): 160-165.
45. Taylor-Papadimitriou J et al (1999) MUC1 and cancer. Biochim Biophys Acta 1455(2-3): 301-313.
46. Brossart P et al (2001) The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 61(18): 6846-6850.
47. Jerome KR et al (1993) Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151(3): 1654-1662.
48. Yamamoto K et al (2005) MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 25(5): 3575-3579.
49. Brossart P et al (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96(9): 3102-3108.
50. Brossart P, Bevan MJ (1997) Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90(4): 1594-1599.
51. Wierecky J et al (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66(11): 5910-5918.
52. Kim Y et al (2003) Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 33(1): 32-38.
53. Kaufman HL et al (2007) Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. J Transl Med 5: 60.
54. Tassi E et al (2008) Carcinoembryonic antigen-specific but not antiviral CD4 + T cell immunity is impaired in pancreatic carcinoma patients. J Immunol 181(9): 6595-6603.
55. Ueda Y et al (2004) Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas. [Clinical trial]. Int J Oncol 24(4): 909-917.
56. Liu KJ et al (2004) Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 10(8): 2645-2651.
57. Babatz J et al (2006) Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligandloaded dendritic cells. Cancer Immunol Immunother 55(3): 268-276.
58. Lesterhuis WJ et al (2006) Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol 17(6): 974-980.
59. Lesterhuis WJ et al (2008) Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 66(2): 118-134.
60. Lesterhuis WJ et al (2010) Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 30(12): 5091-5097.
61. Ambrosini G et al (1997) A novel antiapoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3(8): 917-921.
62. Lopes RB et al (2007) Expression of the IAP protein family is dysregulated in pancreatic cancer cells and is important for resistance to chemotherapy. Int J Cancer 120(11): 2344-2352.
63. Casati C et al (2003) The apoptosis inhibitor protein survivin induces tumor-specific CD8 + and CD4 + T cells in colorectal cancer patients. Cancer Res 63(15): 4507-4515.
64. Otto K et al (2005) Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23(7): 884-889.
65. Tsuruma T et al (2004) Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J Transl Med 2(1): 19.
66. Tsuruma T et al (2008) Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med 6: 24.
67. Karanikas V et al (2008) Baseline levels of CD8 + T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol 129(2): 230-240.
68. Wobser M et al (2006) Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 55(10): 1294-1298.
69. Nagaraj S et al (2007) Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother 30(2): 169-179.
70. Eggert AA et al (1999) Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 59(14): 3340-3345.
71. Moyer JS et al (2008) Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J Immunother 31(9): 885-895.
72. Rossowska J et al (2007) Tissue localization of tumor antigen-loaded mouse dendritic cells applied as an anti-tumor vaccine and their influence on immune response. Folia Histochem Cytobiol 45(4): 349-355.
73. Cohen S et al (2009) Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma. J Immunol 182(3): 1667-1673.
74. De Vries IJ et al (2003) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 63(1): 12-17.
75. Trakatelli M et al (2006) A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8 + T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 55(4): 469-474.
76. Zitvogel L, Tursz T (2005) In vivo veritas. Nat Biotechnol 23(11): 1372-1374.
77. Bedrosian I et al (2003) Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8 + T-cell function in melanoma patients. J Clin Oncol 21(20): 3826-3835.
78. Kyte JA et al (2006) Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13(10): 905-918.
79. Fong L et al (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 166(6): 4254-4259.
80. Mullins DW et al (2003) Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 198(7): 1023-1034.
81. Adema GJ et al (2005) Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 17(2): 170-174.
82. Liau LM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11(15): 5515-5525.
83. Palmer DH et al (2009) A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49(1): 124-132.
84. Trepiakas R et al (2010) Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy 12(6): 721-734.
85. Waisman A, Yogev N (2009) B7-H1 and CD8 + Treg: the enigmatic role of B7-H1 in peripheral tolerance. Eur J Immunol 39(6): 1448-1451.
86. Yoshimura A (2009) Regulation of cytokine signaling by the SOCS and Spred family proteins. Keio J Med 58(2): 73-83.
87. Lob S, Konigsrainer A (2008) Is IDO a key enzyme bridging the gap between tumor escape and tolerance induction? Langenbecks Arch Surg 393(6): 995-1003.
88. Mahnke K et al (2007) Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J Dermatol Sci 46(3): 159-167.
89. Marigo I et al (2008) Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222: 162-179.
90. Li H et al (2009) Cancer-expanded myeloidderived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182(1): 240-249.
91. Bronte V, Mocellin S (2009) Suppressive influences in the immune response to cancer. J Immunother 32(1): 1-11.
92. Llopiz D et al (2009) Peptide inhibitors of transforming growth factor-beta enhance the efficacy of antitumor immunotherapy. Int J Cancer 125(11): 2614-2623.
93. Pellegrini M et al (2009) Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat Med 15(5): 528-536.
94. Vogt TK et al (2009) Novel function for interleukin-7 in dendritic cell development. Blood 113(17): 3961-3968.
95. Gabrilovich DI, Nagaraj S (2009) Myeloidderived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3): 162-174.
96. Lechner MG et al (2011) Functional characterization of human Cd33 + and Cd11b + myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 9: 90.
97. Chatila TA (2009) Regulatory T cells: key players in tolerance and autoimmunity. Endocrinol Metab Clin North Am 38(2): 265-272.
98. Mills KH (2004) Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 4(11): 841-855.
99. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25 + CD4 + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6(4): 345-352.
100. Zhou G et al (2006) Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107(2): 628-636.
101. Xu L et al (2011) In situ prior proliferation of CD4 + CCR6 + regulatory T cells facilitated by TGF-beta secreting DC is crucial for their enrichment and suppression in tumor immunity. PLoS One 6(5): 1-10.
102. Diaz-Montero CM et al (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1): 49-59.
103. Stewart TJ, Smyth MJ (2011) Improving cancer immunotherapy by targeting tumorinduced immune suppression. Cancer Metastasis Rev 30(1): 125-140.
104. Bak SP et al (2008) Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol Immunol 46(2): 258-268.
105. Corzo CA et al (2009) Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182(9): 5693-5701.
106. Ray P et al (2011) Lung myeloid-derived suppressor cells and regulation of inflammation. Immunol Res 50(2-3): 153-158.
107. Wang Z et al (2008) Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation. Transpl Immunol 19(1): 69-73.
108. Yang L et al (2004) Expansion of myeloid immune suppressor Gr + CD11b + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6(4): 409-421.
109. Finke J et al (2011) MDSC as a mechanism of tumor escape from sunitinib mediated antiangiogenic therapy. Int Immunopharmacol 11(7): 856-861.
110. Ko JS et al (2009) Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 15(6): 2148-2157.
111. Kusmartsev S et al (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14(24): 8270-8278.
112. Qian F et al (2009) Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2, 3-dioxygenasemediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res 69(13): 5498-5504.
113. Wang RF et al (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27(2): 181-189.
114. Platz KP et al (2005) IL-2 antagonists: the European perspective. Transplant Proc 37(4): 1783-1784.
115. Duvic M, Talpur R (2008) Optimizing denileukin diftitox (Ontak) therapy. Future Oncol 4(4): 457-469.
116. Ozao-Choy J et al (2009) The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69(6): 2514-2522.
117. Chen YL et al (2008) Depletion of CD4(+) CD25(+) regulatory T cells can promote local immunity to suppress tumor growth in benzo[a] pyrene-induced forestomach carcinoma. World J Gastroenterol 14(38): 5797-5809.
118. Vonderheide RH, June CH (2003) A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy. Immunol Res 27(2-3): 341-356.
119. Kowalczyk DW (2002) Tumors and the danger model. Acta Biochim Pol 49(2): 295-302.
120. Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19(1): 24-32.
121. Seya T et al (2006) Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med 3(1): 31-38, discussion 133-137.
122. Salem ML et al (2009) Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced primeboost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I: C). J Immunol 182(4): 2030-2040.
123. Salem ML et al (2009) The TLR3 agonist poly(I: C) targets CD8 + T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice. Vaccine 27(4): 549-557.
124. Salem ML et al (2006) The adjuvant effects of the toll-like receptor 3 ligand polyinosiniccytidylic acid poly(I: C) on antigen-specific CD8 + T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine 24(24): 5119-5132.
125. Salem ML et al (2005) Defining the antigenspecific T-cell response to vaccination and poly(I: C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother 28(3): 220-228.
126. Salem ML et al (2007) Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8 + T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother 30(1): 40-53.
127. Banchereau J, Palucka AK (2005) Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5(4): 296-306.
128. Fajardo-Moser M et al (2008) Mechanisms of dendritic cell-based vaccination against infection. Int J Med Microbiol 298(1-2): 11-20.
129. Datta SK et al (2003) A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol 170(8): 4102-4110.
130. Edwards AD et al (2003) Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha + DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33(4): 827-833.
131. Lore K et al (2003) Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus-and HIV-1-specific T cell responses. J Immunol 171(8): 4320-4328.
132. Kadowaki N et al (2001) Subsets of human dendritic cell precursors express different tolllike receptors and respond to different microbial antigens. J Exp Med 194(6): 863-869.
133. West MA et al (2004) Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science 305(5687): 1153-1157.
134. Meyer T, Stockfleth E (2008) Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 17(7): 1051-1065.
135. Boullart AC et al (2008) Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57(11): 1589-1597.
136. Jasani B et al (2009) Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27(25-26): 3401-3404.
137. Renn CN et al (2006) TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J Immunol 177(1): 298-305.
138. Tirapu I et al (2009) PolyI: C-induced reduction in uptake of soluble antigen is independent of dendritic cell activation. Int Immunol 21(7): 871-879.
139. Walker J, Tough DF (2006) Modification of TLR-induced activation of human dendritic cells by type I IFN: synergistic interaction with TLR4 but not TLR3 agonists. Eur J Immunol 36(7): 1827-1836.
140. Adams M et al (2003) Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]: poly [C(12) U] (Ampligen R). Vaccine 21(7-8): 787-790.
141. Mailliard RB et al (2004) Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64(17): 5934-5937.
142. Navabi H et al (2009) A clinical grade poly I: C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1): 107-115.
143. Zhu X et al (2007) Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J Transl Med 5: 10.
144. Austyn JM (1998) Dendritic cells. Curr Opin Hematol 5(1): 3-15.
145. Satthaporn S, Eremin O (2001) Dendritic cells (I): biological functions. J R Coll Surg Edinb 46(1): 9-19.
146. Satthaporn S, Eremin O (2001) Dendritic cells (II): role and therapeutic implications in cancer. J R Coll Surg Edinb 46(3): 159-167.
147. Shortman K, Caux C (1997) Dendritic cell development: multiple pathways to nature's adjuvants. Stem Cells 15(6): 409-419.
148. Shortman K et al (1997) Dendritic cells and T lymphocytes: developmental and functional interactions. Ciba Found Symp 204: 130-138, discussion 138-141.
149. Schmidt J et al (2007) Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial. Br J Cancer 97(5): 598-604.
150. Schneider C et al (2004) Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 53(3): 355-361.
151. Schill T et al (2012) Stimulation of pulmonary immune responses by the TLR2/6 agonist MALP-2 and effect on melanoma metastasis to the lung. Exp Dermatol 21(2): 91-98.
152. Pratesi G et al (2005) Therapeutic synergism of gemcitabine and CpGoligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 65(14): 6388-6393.
153. Vanderlocht J et al (2010) Increased tumorspecific CD8 + T cell induction by dendritic cells matured with a clinical grade TLRagonist in combination with IFN-gamma. Int J Immunopathol Pharmacol 23(1): 35-50.
154. Okamoto M, Sato M (2003) Toll-like receptor signaling in anti-cancer immunity. J Med Invest 50(1-2): 9-24.
155. Osada T et al (2006) Dendritic cell-based immunotherapy. Int Rev Immunol 25(5-6): 377-413.
156. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222: 357-368.
157. Cheever MA et al (2008) Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res 14(18): 5692-5699.